N-n Containing (e.g., Aminimine, Hydrazine, Etc.) Patents (Class 514/664)
-
Publication number: 20120219543Abstract: The invention is in the field of disorders of glucose homeostasis therapy. In particular the invention relates to a CFTR inhibitor or an inhibitor of CFTR gene expression for use in the treatment of disorders of glucose homeostasis. The present invention also relates to an in vitro methods for increasing the pool of Ngn3+ endocrine progenitor cells, pancreatic endocrine cells, or ? cell mass obtained from stem cells, wherein said methods comprises the step of contacting stem cells with a CFTR inhibitor or an inhibitor of CFTR gene expression. The present invention also relates to a method of testing a subject thought to have or be predisposed to having disorders of glucose homeostasis, which comprises the step of analyzing a sample of interest from said subject for: (i) detecting the presence of a mutation in the CFTR gene and/or its associated promoter, and/or (ii) analyzing the expression of the CFTR gene.Type: ApplicationFiled: October 19, 2010Publication date: August 30, 2012Inventors: Raphael Scharfmann, Michael Polak, Samia Zertal
-
Publication number: 20120071432Abstract: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-ac-Live agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing the dosage delivered to the subject. In particular embodiments, ICV delivery may be of use for patients who have previously proven to be refractory to systemic administration of CNS agents, in some cases due to systemic side effects, or for those patients whose symptoms are of sufficient severity to warrant more aggressive therapeutic intervention. ICV administration allows not only lower systemic concentration but also higher therapeutically effective concentration within the CNS.Type: ApplicationFiled: March 18, 2011Publication date: March 22, 2012Applicant: The Regents of the University of ColoradoInventors: Daniel J. Abrams, Raymond Bunch, Tom Anchordoquy, Karen Elizabeth Stevens
-
Patent number: 7879914Abstract: Methods for treating viral infections using polyamine analogs, including mitoguazone (MGBG), are provided. In these methods, polyamine analogs destroy macrophages that act as viral reservoirs, facilitating the destruction of the viruses that dwell within the macrophages. Examples of viral infections that may be treated with the present methods include, but are not limited to, infections from human immunodeficiency viruses. These methods differ from previous methods of treatment using polyamine analogs, wherein the polyamine analogs were administered only as anti-tumor agents.Type: GrantFiled: September 25, 2006Date of Patent: February 1, 2011Assignee: Pathlogica LLCInventors: Michael S. McGrath, Kenneth G. Hadlock
-
Publication number: 20100305152Abstract: The shikimate pathway links metabolism of carbohydrates to biosynthesis of aromatic compounds, which is an attractive target for the rational drug and herbicide design because it is essential in algae, higher plants, bacteria, and fungi, but absent from mammals. Thus, the present invention provides a method of inhibiting the growth of bacteria or fungi, especially Helicobacter pylori, through inhibiting enzymes in the shikimate pathway.Type: ApplicationFiled: May 27, 2009Publication date: December 2, 2010Applicant: NATIONAL TSING HUA UNIVERSITYInventors: WEN-CHING WANG, WEN-CHI CHENG, JINN-MOON YANG
-
Publication number: 20100062055Abstract: Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: where R is a branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) a —S—N?O moiety, (b) a —O—N?O moiety, or (c) a moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described.Type: ApplicationFiled: November 17, 2009Publication date: March 11, 2010Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Robert A. Herrmann, Wendy Naimark
-
Publication number: 20090270470Abstract: Compounds of formula I, wherein R1, Z, X, Y, M and R2 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical composition containing the same, methods of using the same for therapeutic purposes and methods of making the same.Type: ApplicationFiled: May 8, 2006Publication date: October 29, 2009Applicant: AstraZeneca ABInventors: Catrin Jonasson, Hakan Molin, Berit Molin, Didier Rotticci
-
Publication number: 20080312098Abstract: The use of the single nucleotide polymorphism (SNP) at position ?(97) of the GIP gene for the identification of a cardiovascular disease or of an increased risk for developing a cardiovascular disease in a biological sample taken from an individual to be examined.Type: ApplicationFiled: May 3, 2006Publication date: December 18, 2008Applicant: SANOFI-AVENTISInventors: Detlef Kozian, Matthias Herrmann, Karl-Ernst Siegler, Jean-Francois Deleuze, Sylvain Ricard, Sandrine Mace
-
Publication number: 20080226753Abstract: The present invention discloses Resistance Management (RM) practices that are critical to safeguarding Bacillus thuringiensis as a natural resource and to sustaining genetically modified crops that express Bt toxins for managing ECB and WCRW. The methods involve blending seed transformed with a nucleic acid encoding a different pesticidal protein, where both proteins target the same pest, but use different modes of pesticidal action. The seed can be also treated with pesticidal agents.Type: ApplicationFiled: March 29, 2005Publication date: September 18, 2008Applicant: PIONEER HI-BRED INTERNATIONAL, INC.Inventor: Daniel J. Cosgrove
-
Patent number: 6852341Abstract: Disclosed is both a method and composition for controlling deleterious organisms, such as insects, nematodes and weeds while maintaining beneficial soil organisms, by applying a compound comprised of a liquid medium and comprising an azide and an amino acid polymer. The azide can be selected from the group consisting of sodium azide and potassium azide or a combination of the two. The composition provides an effective pesticide, without causing significant harm to the environment. The composition may be applied to soil to control a population of a deleterious organism.Type: GrantFiled: October 8, 2002Date of Patent: February 8, 2005Assignee: Auburn UniversityInventor: Rodrigo Rodriguez-Kabana
-
Publication number: 20040248871Abstract: A subject of the invention is the use of lysyl oxidase inhibitors in the context of the implementation of in vitro cell culture methods which are capable of being used in tissue therapy, or cell therapy, or in experimental pharmacology.Type: ApplicationFiled: July 22, 2004Publication date: December 9, 2004Inventors: Jean Farjanel, Odile Damour born Baudoux, Pascal Sommer, Fabienne Raye, Michel-Henri Fessy
-
Patent number: 6812251Abstract: The invention provides a method of inhibiting tumor growth by contacting the tumor with a composition containing a taurine compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death.Type: GrantFiled: March 15, 2002Date of Patent: November 2, 2004Assignee: Rhode Island HospitalInventors: Paul Calabresi, Bai-Chuan Pan, James Darnowski
-
Publication number: 20040198840Abstract: A hydrazide substrate is targeted by disease activated protease to shutdown protein products required by viral infections, cancer, and other diseases. Protease cleavage innately targets peptide bonds that are simulated in the hydrazide substrate molecule. Cleavage action releases the reactive hydrazine moiety that bonds to the protease enzyme structure causing its dysfunctional shutdown. That shutdown stops incessant disease activity that holds cell maintenance systems at bay, and also halts the production of proteins and peptides necessary for disease activity and proliferation as viral coat proteins and metastatic cancer proteins exemplify. Other uses for the hydrazide substrates mechanism also exists to shutdown protease systems innate to microorganisms as a way to halt production of peptide signals that induced cell division, growth, or reproduction of infectious organisms.Type: ApplicationFiled: March 30, 2004Publication date: October 7, 2004Inventor: Reuben Edwin Deloach
-
Publication number: 20040106654Abstract: The present invention is directed to hydrazono compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.Type: ApplicationFiled: July 21, 2003Publication date: June 3, 2004Inventors: David John Smith, Markku Jalkanen, Ferenc Fulop, Laszlo Lazar, Zsolt Szakonyi, Gabor Bernath
-
Publication number: 20030229138Abstract: Disclosed are compounds of formula: 1Type: ApplicationFiled: May 22, 2002Publication date: December 11, 2003Inventors: Heinrich Schostarez, Robert Alan Chrusciel, Rebecca S. Centko
-
Patent number: 6624202Abstract: The present invention is directed to hydrazino compounds that function as inhibitors of copper-containing amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula: or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R1 to R8 and X are as defined herein.Type: GrantFiled: July 5, 2001Date of Patent: September 23, 2003Assignee: Biotie Therapies Corp.Inventors: David John Smith, Markku Jalkanen, Ferenc Fülöp, László Lázár, Zsolt Szakonyi, Gábor Bernáth
-
Patent number: 6586478Abstract: Methods and compositions for improving sleep in individuals with sleep disorders or other conditions which interfere with normal sleep via administration of a NO-mimetic are provided.Type: GrantFiled: February 22, 2001Date of Patent: July 1, 2003Assignee: Cellegy CanadaInventors: C. Bruce Ackman, Michael A. Adams, Jeremy P. W. Heaton, Jodan D. Ratz
-
Publication number: 20020198184Abstract: The present invention provides a medical composition containing, as an active constituent, a nitroetheneamine derivative represented by the formula (I): 1Type: ApplicationFiled: April 29, 2002Publication date: December 26, 2002Applicant: ISHIHARA SANGYO KAISHA LTD.Inventors: Fuminori Kato, Keizo Miyata, Hirohiko Kimura, Kazuhiro Yamamoto, Hiroyuki Ikegami, Hiromi Takeo
-
Publication number: 20020173521Abstract: The present invention is directed to hydrazono compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to aberrations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases.Type: ApplicationFiled: July 5, 2001Publication date: November 21, 2002Applicant: Biotie Therapies Corp.Inventors: David John Smith, Markku Jalkanen, Ferenc Fulop, Lazlo Lazar, Zsolt Szakonyi, Gabor Bernath
-
Patent number: 6153633Abstract: Disclosed are stable microbicidal compositions of 3-isothiazolone compounds and azobiscarbonyl compounds. Also disclosed are methods of stabilizing 3-isothiazolone compounds against chemical decomposition by combining with the 3-isothiazolones a stabilizing amount of an azobiscarbonyl compound.Type: GrantFiled: June 16, 1999Date of Patent: November 28, 2000Assignee: Rohm and Haas CompanyInventors: Tirthankar Ghosh, David Willard Potter
-
Patent number: 6110921Abstract: The invention relates to a method of treating psychotic disorders comprising a biodegradable and biocompatible microparticle composition comprising a 1,2-benzazole of the formula ##STR1## and the pharmaceutically acceptable acid addition salts thereof.Type: GrantFiled: February 18, 1999Date of Patent: August 29, 2000Assignees: Alkermes Controlled Therapeutics Inc. II, Janssen PharmaceuticaInventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
-
Patent number: 6083908Abstract: Compounds of Formula I ##STR1## and their use for treating medical disorders resulting from a deficiency in growth hormone are disclosed, wherein R.sup.1, R.sup.2, R.sup.3a, R.sup.4a, R.sup.5a, G, J and D are as defined in the specification.Type: GrantFiled: January 12, 1999Date of Patent: July 4, 2000Assignee: Novo Nordisk A/SInventor: Michael Ankersen
-
Patent number: 5622995Abstract: A method is provided for controlling the proliferation of molluscs in target habitat by applying to the habitat a compound or mixture of compounds which are amines, ethoxylated amines, quaternary amines, ethoxylated quaternary amines and cyclic amines.Type: GrantFiled: August 15, 1994Date of Patent: April 22, 1997Assignee: Electric Power Research Institute, Inc.Inventors: Billy D. Fellers, Arthur J. Freedman, Thomas M. Laronge
-
Patent number: 5530028Abstract: Insecticidal compounds having the formula N-(2-R.sup.a -3-R.sup.b -4-R.sup.h -benzoyl)-N'-(2-R.sup.c -3-R.sup.d -4-R.sup.e -5-R.sup.f -benzoyl)-N'-R.sup.g -hydrazine wherein R.sup.a is a halo or lower alkyl; R.sup. b is lower alkoxy, optionally substituted with halo (preferably fluoro); R.sup.c is selected from hydrogen, halo, lower alkyl, lower alkoxy, lower alkoxy lower alkyl, and nitro; R.sup.d, R.sup.e and R.sup.f are each independently selected from hydrogen, bromo, chloro, fluoro, lower alkyl, lower alkoxy, and lower alkoxy lower alkyl; R.sub.g is a (C.sub.4 -C.sub.6)alkyl; R.sup.h is hydrogen, lower alkoxy, lower alkyl, or when taken together with R.sup.b is methylenedioxy (--OCH.sub.2 O--), 1,2-ethylenedioxy (--OCH.sub.2 CH.sub.2 O--), 1,2-ethyleneoxy (--CH.sub.2 CH.sub.2 O--) or 1,3-propyleneoxy (--CH.sub.2 CH.sub.2 CH.sub.2 O--) wherein an oxo atom is located at the R.sup.b position; and the substituents R.sup.c and R.sup.d, or R.sup.d and R.sup.e, or R.sup.e and R.sup.Type: GrantFiled: September 29, 1993Date of Patent: June 25, 1996Assignee: Rohm and Haas CompanyInventors: Zev Lidert, Dat P. Le, Robert E. Hormann, Thomas R. Opie
-
Patent number: 5527787Abstract: A novel pharmaceutical composition having anti-bacterial and antiviral activity and method of treating diseases caused by bacterial and viral pathogens through stimulation of the immunologic system. The composition comprises selected amounts of chlorambucil, procarbazine and cyclophosphamide. Melphalan and liothyronine are primary options. Calcium may also be included as a desirable supplement. The method includes administering these components to a patient in an ordered, time-released manner.Type: GrantFiled: November 15, 1993Date of Patent: June 18, 1996Inventors: Zdzislaw Fiutowski, Leszek J. Fiutowski
-
Patent number: 5183687Abstract: In accordance with the present invention, a method is provided for treating poultry for coccidiosis. The method comprises administering an effective amount of a biologically-active copolymer on the poultry with coccidiosis, the octablock copolymer being selected from the group consisting of an octablock copolymer having the following formula: ##STR1## and an octablock copolymer having the following formula: ##STR2## wherein: the mean aggregate molecular weight of the portion of the octablock copolymer represented by the polyoxypropylene is between approximately 5000 and 7000 daltons;a is a number such that the portion represented by polyoxyethylene constitutes between approximately 10% to 40% of the compound by weight; andb is a number such that the polyoxypropylene portion of the total molecular weight of the octablock copolymer constitutes between approximately 50% and 90% of the compound by weight.Type: GrantFiled: November 7, 1990Date of Patent: February 2, 1993Assignee: Emory UniversityInventors: Robert L. Hunter, William L. Ragland
-
Patent number: 5177083Abstract: A method to treat or prevent retroviral infection by administering a novel conjugate is described. Lucifer Yellow and its analogs are conjugated to compounds having carbonyl functional groups for reaction with the semicarbazide moiety of Lucifer Yellow to obtain the semicarbazone conjugate.Type: GrantFiled: September 11, 1989Date of Patent: January 5, 1993Assignee: The Scripps Clinic and Research FoundationInventors: Darryl C. Rideout, John Elder
-
Patent number: 4996220Abstract: A clathrate compound is produced if a powdery host compound which reacts with a microbicide to form the clathrate compound is added into an aqueous solution of the microbicide. If the microbicide is separated from the clathrate compound, a microbicide of high purity can be obtained.Type: GrantFiled: April 9, 1990Date of Patent: February 26, 1991Assignee: Kurita Water Industries Ltd.Inventors: Ayako Sekikawa, Hideo Sugi, Ryoichi Takahashi